Pharos iBio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Pharos iBio is a drug-discovery company focused on developing new medicines for rare and hard-to-treat diseases, particularly cancers.
It sits at the research and early clinical stage of the pharmaceutical supply chain, advancing drug candidates toward regulatory approval rather than supplying commercial products. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company's core asset is its proprietary AI-driven drug-discovery platform, called Chemiverse, which integrates large compound databases with multi-omics analysis to identify and optimize small-molecule drug candidates.
Summary is AI-generated and may contain errors · figures from DART filings
Its lead drug candidate, Lasmotinib, has received orphan-drug designation from the US FDA, the Korean MFDS, and the European EMA, a status that can confer priority review and post-approval market exclusivity in those jurisdictions.
Pharos iBio in five facts
What does Pharos iBio do?
Pharos iBio is a drug-discovery company focused on developing new medicines for rare and hard-to-treat diseases, particularly cancers.
Where is Pharos iBio listed and in which sector?
Pharos iBio (Korean name: 파로스아이바이오) trades under KRX code 388870 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is Pharos iBio?
Its market capitalisation was US$61M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.